For how we live.
The TRACK trial was stopped early for futility. The blood thinner failed to reduce a composite of cardiovascular events, while major bleeding rose by half. Bayer, which makes the drug, was a listed collaborator.
In the 1,658-person PUSH trial, a behavioural programme with financial incentives raised urine volume but left symptomatic stone recurrences unchanged over two years — 19% against 20% with usual care.
Final ALIGN results show the endothelin blocker preserved kidney function over 2.5 years in a rare kidney disease, yet the difference at week 136 just missed statistical significance (p=0.057).
In the FIND-CKD trial, non-diabetic patients on finerenone lost kidney function at 3.3 versus 4.0 ml/min/1.73 m² a year — a small edge that extends a diabetes drug to a new group.
Voyxact cut urinary protein by about half at nine months in the VISIONARY trial. Whether that slows kidney decline is the question the accelerated approval leaves open until 2027.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.